APAC Oral GLP-1 Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.02 BnPlaceholder estimate
Estimate 2025$1.37 Bn24.5% of the global market
Projected 2034$18.54 Bn 1,256%Adds $17.17 Bn over 9 forecast years
CAGR 2025–203433.6%Faster than 98% of 180 Pharmaceuticals markets here
Key players5
APAC is 24.52% of the global market.
Among regions, the largest is North America at $3.15 Bn.
Fastest growing: APAC (this report) at 33.6% a year.
APAC ranks 2nd of 6 by size among regions.
Market size projection
APAC
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$17.17 Bn total, 2026–2034
Year-by-year market size, 2024–2034
Oral GLP-1 Drugs Market market size by year, APAC
Year
Market size
Change that year
Since 2025
2024 (estimate)
$1.02 Bn
—
—
2025 (base)
$1.37 Bn
+$343.9 Mn
—
2026 (forecast)
$1.83 Bn
+$459.4 Mn
+33.6%
2027 (forecast)
$2.44 Bn
+$613.7 Mn
+78.5%
2028 (forecast)
$3.26 Bn
+$820.0 Mn
+138.5%
2029 (forecast)
$4.36 Bn
+$1.10 Bn
+218.6%
2030 (forecast)
$5.82 Bn
+$1.46 Bn
+325.6%
2031 (forecast)
$7.77 Bn
+$1.96 Bn
+468.6%
2032 (forecast)
$10.39 Bn
+$2.61 Bn
+659.7%
2033 (forecast)
$13.88 Bn
+$3.49 Bn
+915%
2034 (forecast)
$18.54 Bn
+$4.66 Bn
+1,256%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics, Viking Therapeutics (see all)
Active clinical trials
2 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Oral GLP-1 Drugs Market Analysis Executive Summary
Oral GLP-1 drugs deliver GLP-1 based therapy as a tablet instead of an injection, making treatment easier for people with diabetes or obesity.
Key segments of the oral GLP-1 Drugs market include drug (Oral Semaglutide, Orforglipron and Danuglipron) and application (Type 2 Diabetes and Obesity).
Asia Pacific Oral GLP-1 Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Oral GLP-1 Drugs Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the oral GLP-1 Drugs market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the oral GLP-1 Drugs market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Oral GLP-1 Drugs Market in APAC
The oral GLP-1 Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Oral GLP-1 Drugs Market in APAC
Oral GLP-1 Drugs in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], BPOM (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Drug Administration of Vietnam (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 2 studies on Oral GLP-1 Drugs that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oral GLP-1 Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Application
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Eli Lilly and Company
7.3 Pfizer
7.4 Structure Therapeutics
7.5 Viking Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The oral GLP-1 Drugs market can be segmented based on various criteria, including drug, application and end user. Here's a breakdown of the market segmentation
What doctors and scientists are doing in Oral GLP-1 Drugs right now, from free public sources.
Clinical trials
2 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Oral GLP-1 Drugs market in Asia Pacific?
Placeholder estimate: about $1.37 Bn in 2025, rising to about $18.54 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Oral GLP-1 Drugs market in Asia Pacific growing?
Placeholder estimate: about 33.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Oral GLP-1 Drugs market report cover?
The report splits the market by drug (Oral Semaglutide, Orforglipron, Danuglipron, Others), application (Type 2 Diabetes, Obesity) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Oral GLP-1 Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics and Viking Therapeutics.
What is driving the Oral GLP-1 Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market.
How many clinical trials on Oral GLP-1 Drugs are running in Asia Pacific?
2 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Oral GLP-1 Drugs?
PubMed lists 65 papers on Oral GLP-1 Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.